Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

✍ Scribed by Palfi, Stéphane; Gurruchaga, Jean Marc; Ralph, G Scott; Lepetit, Helene; Lavisse, Sonia; Buttery, Philip C; Watts, Colin; Miskin, James; Kelleher, Michelle; Deeley, Sarah; Iwamuro, Hirokazu; Lefaucheur, Jean Pascal; Thiriez, Claire; Fenelon, Gilles; Lucas, Cherry; Brugières, Pierre; Gabriel, Inanna; Abhay, Kou; Drouot, Xavier; Tani, Naoki; Kas, Aurelie; Ghaleh, Bijan; Le Corvoisier, Philippe; Dolphin, Patrice; Breen, David P; Mason, Sarah; Guzman, Natalie Valle; Mazarakis, Nicholas D; Radcliffe, Pippa A; Harrop, Richard; Kingsman, Susan M; Rascol, Olivier; Naylor, Stuart; Barker, Roger A; Hantraye, Philippe; Remy, Philippe; Cesaro, Pierre; Mitrophanous, Kyriacos A

• Book ID: 121455746
• Publisher: The Lancet
• Year: 2014
• Tongue: English
• Weight: 657 KB
• Volume: 383
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/S0140-6736(13)61939-X